Pollens et allergies croisées : quel langage adopter en consultation ?

1. Poncet P, Sénéchal H. Actualités des réactions croisées pollen-aliment. Rev fr Allergol 2019;59:543–554.
2. Werfel T, Asero R, Ballmer-Weber BK, Beyer K, Enrique E, Knulst AC, et al. Position paper of the EAACI: food allergy due to immunological cross-reactions with common inhalant allergens. Allergy. 2015;70:1079-90. 
3. Han Y, Kim J, Ahn K. Food allergy. Korean J Pediatr. 2012;55(5):153-8.
4. Bouvier M, Van Der Brempt X, Nosbaum A, Cordier JM, Chérih C, Frappaz A, et al. L’induction de tolérance orale dans l’allergie aux rosacées. Rev fr Allergol. 2014;54(3):127-133. 
5. Bouvier M, Hacker M. Effi cacité de l’induction de tolérance à la pomme Golden crue selon un protocole Rush réalisé chez 28 patients allergiques aux rosacées. Rev fr Allergol. 2018;58(3):228. 
6. Morisset M. Immunothérapie orale et allergie alimentaire. Rev fr Allergol. 2011;51(3):295-300. 
7. Ponthieux F, Revercez B, Corazza F, Doyen V. Allergie alimentaire aux PR10 sans allergie au pollen de bouleau. Rev fr Allergol. 2021;61(5):343-4. 
8. Didier A, Postigo M-A, Prévot G, Têtu L, Dutau

Rhinite allergique : un comprimé, un spray nasal ou les deux ? 

1. Brożek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S et al. Allergic Rhinitis and its Impact on Asthma
2. (ARIA) guidelines—2016 revision. J Allergy Clin Immunol. 2017;140(4):950-958.
3. SFORL. Prise en charge diagnostique et thérapeutique des rhinites allergiques par l’ORL (hors rhinites professionnelles).
4. 2020. https://www.sforl.org/wp-content/uploads/2020/07/Recommandation-SFORL-P…
5. Watelet JB, Vermeiren J, Van Cauwenberge P. De l’intérêt de la corticothérapie nasale dans la rhinite allergique de l’enfant. Rev
6. Fr Allergol Immunol Clin. 2001;41(7):628-33. Demoly P, Klossek JM, Serrano É, Didier A. Effi cacité des corticoïdes par voie nasale sur les symptômes oculaires de la rhinite
7. allergique. Rev Fr Allergol. 2010;50(5):419-25.
8. Demoly P, Sévenier F, Dreyfus I, Serrano E. Observatoire des pratiques et usages de la corticothérapie par voie nasale dans les
9. rhinites allergiques intermittentes en médecine générale en France. Rev Fr Allergol Immunol Clin. 2007;47(1):2-8.
10. Bensch GW. Safety of intranasal corticosteroids. Ann Allergy Asthma Immunol 2016;117:601-5.

Orage, pollens, allergie : le mauvais cocktail !

1. Thibaudon M, Sauleau EA, Oliver G, Poirot A, Heaulme R, Harscoat S, de Blay F. Moisissures, orages, asthme. Rev Fr Allergol. 2014, 54 (3): 124-6.

Le coût économique des allergies respiratoires

1. Valovirta E (ed). EFA Book on Respiratory Allergy in Europe. Raise awareness, relieve the Burden, 2011.
2. Enquête European Federation of Allergy, 2011.
3. Wallaert B, Birnbaum J. Le grand livre des allergies, Fédération française d’allergologie, 2014.
4. Belhassen M, Demoly P, Bloch-Morot E et al. Costs of perennial allergic rhinitis and allergic asthma increase with severity and poor disease control. Allergy, 2017 Jun;72(6):948-958. doi: 10.1111/all.13098. Epub 2017 Jan 11. PMID: 27886386 DOI: 10.1111/all.13098

Rhinite allergique de l’enfant et l’adolescent

1. Devillier P, Bousquet PJ, Grassin-Delyle S, Salvator H, Demoly P, Bousquet J, de Beaumont O. Comparison of outcome measures in allergic rhinitis in children, adolescents and adults. Pediatr Allergy Immunol 2016;27(4):375-81.
2. Blaiss MS, Hammerby E, Robinson S, Kennedy-Martin T, Buchs S. The burden of allergic rhinitis and allergic rhinoconjunctivitis on adolescents: A literature review. Ann Allergy Asthma Immunol 2018;121(1):43-52.e3.
3. Liu J, Zhang X, Zhao Y, Wang Y. The association between allergic rhinitis and sleep: A systematic review and meta-analysis of observational studies. PLoS One 2020;15(2):e0228533.
4. Walker S, Khan-Wasti S, Fletcher M, Cullinan P, Harris J, Sheikh A. Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case-control study. J Allergy Clin Immunol 2007;120(2):381-7.
5. Carr TF, Stern DA, Halonen M, Wright AL, Martinez FD. Non-atopic rhinitis at age 6 is associated with subsequent development of asthma. Clin Exp Allergy 2019;49(1):35-43.

Nouvelle nomenclature en allergologie

1. Jutel M, Agache I, Zemelka-Wiacek M, Akdis M, Chivato T, Del Giacco S, et al. Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper. Allergy. 2023 Nov;78(11):2851-2874. doi: 10.1111/ all.15889. 

2. Coombs PR, Gell PG. Classifi cation of allergic reactions responsible for clinical hypersensitivity and disease. In: Gell RR, ed. Clinical Aspects of Immunology. Oxford University Press; 1968:575-96.

3. Johansson SG, Hourihane JO, Bousquet J, Bruijnzeel-Koomen C, Dreborg S, Haahtela T et al. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy. 2001;56(9):813-824. doi:10.1034/j.1398-9995.2001. t01-1-00001.

Le PAI en 4 questions

1. https://eduscol.education.fr/  

2. A. Gloaguen A, Cesareo E, Vaux J et al. Prise en charge de l’anaphylaxie en médecine d’urgence. Recommandations de la Société française de médecine d’urgence (SFMU) en partenariat avec la Société française d’allergologie (SFA) et le Groupe francophone de réanimation et d’urgences pédiatriques (GFRUP), et le soutien de la Société pédiatrique de pneumologie et d’allergologie (SP2A), Revue française d’allergologie 2017;57(8): 595-614, ISSN 1877-0320.

La place des anti-leucotriènes dans l’asthme de l’enfant et de l’adolescent. 

1. Castro-Rodriguez JA, Rodriguez-Martinez CE, Ducharme FM. Daily inhaled corticosteroids or montelukast for preschoolers with asthma or recurrent wheezing: A systematic review. Pediatr Pulmonol 2018;53(12):1670-7.

2. Fitzpatrick AM, Jackson DJ, Mauger DT, et al. Individualized therapy for persistent asthma in young children. J Allergy Clin Immunol 2016;138(6): 1608-18.

3. Ostrom NK, Decotiis BA, Lincourt WR, et al. Comparative effi cacy and safety of low-dose fl uticasone propionate and montelukast in children with persistent asthma. J Pediatr 2005; 147(2):213-20.

4. Sorkness CA, Lemanske RF, Mauger DT, et al. Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial. J Allergy Clin Immunol 2007;119(1):64-72.

5. Chauhan BF, Ducharme FM. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/ or chronic asthma in adults and children. Cochrane Database Syst Rev 2012;5:CD002314.

6. Stelmach I, et al. Effect of different antiasthmatic treatments on exercise-induced bronchoconstriction in children with asthma. J Allergy Clin Immunol 2008.

7. Lemanske RF Jr, Mauger DT, Sorkness CA, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med 2010;362(11):975-85.

8. Fogel RB, Rosario N, Aristizabal G, et al. Effect of montelukast or salmeterol added to inhaled fl uticasone on exercise-induced bronchoconstriction in children. Ann Allergy Asthma Immunol 2010;104(6):511-7.

9. https://ginasthma.org/wp-content/uploads/2023/07/GINA-2023-Pocket-Guide-WMS.pdf 

10. Deschildre A, Abou-Taam R, Drummond D, et al. Mise à jour des recommandations (2021) pour la prise en charge et le suivi des patients asthmatiques adolescents (de 12 ans et plus) sous l’égide de la Société de pneumologie de langue française (SPLF) et de la Société pédiatrique de pneumologie et allergologie (SP2A). Version longue [Update of the 2021 Recommendations for the management of and follow-up of adolescent asthmatic patients (over 12 years) under the guidance of the French Society of Pulmonology and the Paediatric Society of Pulmonology and Allergology. Long version]. Rev Mal Respir 2022.

Fake news : mais c’est quoi un œdème de Quincke, en fait ? 

1. Reshef A, Kidon M, Leibovich I. The Story of Angioedema: from Quincke to Bradykinin. Clin Rev Allergy Immunol 2016;51(2):121-39. doi: 10.1007/s12016-016-8553-8. PMID: 27287037.

Bonnes pratiques dans l’asthme de l’adulte

1. Wermuth HR, Badri T, Takov V. Montelukast 2023. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing 2024. PMID: 29083616.

2. Ducharme FM, Lasserson TJ, Cates CJ. Addition to inhaled corticosteroids of long-acting beta2-agonists versus antileukotrienes for chronic asthma. Cochrane Database of Systematic Reviews 2011(5).

3. Raherison-Semjen C, Guilleminault L, Billiart I, Chenivesse C, De Oliveira A, Izadifar A, et al. Updated guidelines (2021) for management and follow-up of asthmatic patients of the French Society of Pneumology (SPLF) and the French Society of Pediatric Pneumology and Allergology (SP2A). Short version. Respir Med Res 2022;81:100898.

4. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med 1998;158(11):1213-20. 

5. Altman LC, Munk Z, Seltzer J, Noonan N, Shingo S, Zhang J, Reiss TF. A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. Montelukast Asthma Study Group. J Allergy Clin Immunol 1998;102(1):50-6.

6. Leff JA, Busse WW, Pearlman D, Bronsky EA, Kemp J, Hendeles L, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 1998 16;339(3):147-52.

7. Chauhan BF, Ducharme FM. Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma. Cochrane Database Syst Rev. 2014 24;2014(1):CD003137.

La stratégie MART chez l’enfant et l’adolescent asthmatiques

1. https://ginasthma.org/wp-content/uploads/2019/09/GINA-2019-main-Pocket-Guide-French-wms.pdf

2. Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 2006;368:744-53.

3. Rabe KF, Pizzichini E, Ställberg B, Romero S, Balanzat AM, Atienza T, et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized,double-blind trial. Chest 2006;129:246-56.

4. Kuna P, Peters MJ, Manjra AI, Jorup C, Naya IP, Martinez-Jimenez NE, Buhl R. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract 2007;61:725-36.

5. Jorup C, Lythgoe D, Bisgaard H. Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma. Eur Respir J 2018;51(1):1701688.

6. Deschildre A, Abou-Taam R, Drummond D, Giovannini-Chami L, Labouret G, Lejeune S, et al. Mise à jour des recommandations (2021) pour la prise en charge et le suivi des patients asthmatiques adolescents (de 12 ans et plus) sous l’égide de la Société de pneumologie de langue française (SPLF) et de la Société pédiatrique de pneumologie et allergologie (SP2A). Version longue [Update of the 2021 Recommendations for the management of and follow-up of adolescent asthmatic patients (over 12 years) under the guidance of the French Society of Pulmonology and the Paediatric Society of Pulmonology and Allergology. Long version]. Rev Mal Respir 2022;39(2):e1-e31.

7. Reddel HK, Bacharier LB, Bateman ED, Brightling CE, Brusselle GG, Buhl R, et al. Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes. Am J Respir Crit Care Med 2022;205(1):17-35.